Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Uchida

Showing results (221-230 of 229) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 229 results.
BMC Cancer|April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter studyKazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumabMinoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
International Journal of Clinical Oncology|October 8, 2024
Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter studyMinoru Kato, Rikiya Taoka, Jun Miki, et al.
Scientific Reports|August 2, 2024
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapyMoto Yaga, Kana Hasegawa, Shunya Ikeda, et al.
Pageof 23

Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
BMC Cancer|April 2, 2021
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter studyKazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, et al.
Clinical Lung Cancer|June 29, 2025
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)Yoshihiko Sakata, Go Saito, Shinya Sakata, et al.
Lung Cancer (Amsterdam, Netherlands)|December 14, 2024
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort studyJun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, et al.
JAMA Network Open|February 24, 2023
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial EligibilityDaichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, et al.
Thoracic Cancer|June 3, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective StudyKeijiro Yamauchi, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 21, 2021
Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumabMinoru Kato, Takashi Kobayashi, Yoshiyuki Matsui, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
International Journal of Clinical Oncology|October 8, 2024
Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter studyMinoru Kato, Rikiya Taoka, Jun Miki, et al.
Scientific Reports|August 2, 2024
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapyMoto Yaga, Kana Hasegawa, Shunya Ikeda, et al.
Pageof 23